Table 1 Baseline characteristics of COVID-19 patients and controls
From: DNA methylation predicts the outcome of COVID-19 patients with acute respiratory distress syndrome
Variable | COVID-19 N = 100a | Controls N = 33a | p-valub |
|---|---|---|---|
Age | 49 (42, 59) | 40 (35, 45) | < 0.001 |
Gender (male) | 95 (95%) | 33 (100%) | 0.3 |
BMI (kg/m2) | 27.2 (24.6, 31.0) | 29.3 (26.4, 31.2) | 0.12 |
Ethnicity | |||
East Africa | 0 (0%) | 1 (3.0%) | < 0.001 |
Middle East | 5 (5.0%) | 11 (33%) | |
North Africa | 1 (1.0%) | 0 (0%) | |
Northeast Africa | 5 (5.0%) | 4 (12%) | |
South Asia | 78 (78%) | 15 (45%) | |
Southeast Asia | 9 (9.0%) | 2 (6.1%) | |
Western Asia | 2 (2.0%) | 0 (0%) | |
Duration of MV (days) | 8 (4, 19) | – | |
ICU LoS (days) | 15 (10, 27) | – | |
Hospital LoS (days) | 27 (20, 44) | – | |
ECMO | 12 (12%) | – | |
Nosocomial infections | 55 (55%) | – | |
Convalescent plasma therapy | 30 (30%) | – | |
Diabetes status | |||
Non diabetes | 55 (55%) | – | – |
Pre-diabetes | 4 (4.0%) | – | |
Diabetes | 41 (41%) | – | |
Hypertension | 43 (43%) | – | – |
Coronary artery disease | 6 (6.0%) | – | – |
Chronic kidney failure | 11 (11%) | – | – |
Chronic heart failure | 2 (2.0%) | – | – |